ONC
NEUTRALOncimmune Holdings Announces Change in Shareholding
The healthcare company has announced a change in shareholding, with Balderton Capital III, LP reducing its stake in the business.
Oncimmune Holdings
1.1400GBX
-4.20%
Market Cap
1.27M
Volume
432.31k
132% of avg
P/E Ratio
0.06
EPS (TTM)
0.2
Beta
1.81
Day Range
1.0100p - 1.3900p
52 Week Range
0.0114p1.1400p26.0000p
1.1400p
Upcoming Events
FY2025 Results Release
FY2025 Results Release (31 August 2025)
High Impact Event
ONC
VERY BADOncimmune Holdings Faces Administration and Delisting
The healthcare company is unable to find a buyer or raise capital, leading to administration and suspension of trading.
ONC
NEUTRALOncimmune Seeks Strategic Partnerships and Financing to Extend Cash Runway
The healthcare company is seeking strategic partnerships and financing to address operational and financial challenges, as it aims to extend its cash runway beyond April 2025.
ONC
NEUTRALOncimmune Holdings Announces Change in Major Shareholding
The biotechnology company has announced a change in major shareholding, a routine regulatory update that is unlikely to significantly affect the stock.
ONC
NEUTRALOncimmune Holdings Announces General Meeting to Approve Annual Report
The precision medicine company has announced a General Meeting to approve its annual report, a standard regulatory update with no major implications.
ONC
NEUTRALOncimmune Reports 138% Revenue Growth Amid Ongoing Losses in FY2024 Results
The precision medicine company reported a 138% revenue increase but continues to face losses. A debt restructuring and new contracts signal potential, yet industry challenges and cash flow concerns persist.
ONC
NEUTRALOncimmune Holdings Announces Change in Major Shareholding
The healthcare company has announced a change in major shareholding, with Spreadex Ltd reducing its stake. The notification is a standard regulatory update with no apparent impact on the business.
ONC
NEUTRALOncimmune Announces Notice of Annual General Meeting
The healthcare company has provided notice of its upcoming Annual General Meeting, with the annual report expected to be published by the end of February.
ONC
GOODOncimmune Delivers Strong Revenue Growth in FY2024 and Expects Further Gains in FY2025
The healthcare company reported robust revenue growth in the current year and expects further gains in the next, as it works to reduce costs and strengthen its financial position.